Biological Prospects, the parent company of Petthrive and its sister company Equithrive, is the pioneer in canine and equine Resveratrol Therapy. The company has an ongoing focus on research, development and sales of products that promote a healthy inflammatory response in animals to support joint health and metabolic health.
A company built on science
In 2007, Dr. Patrick Lawless was working as a biopharmaceutical research scientist developing new anti-inflammatory drugs when he witnessed Kentucky Derby winner Barbaro’s tragic breakdown in the Preakness Stakes. With the entire nation, he followed the courageous battle waged by this horse and his caretakers until he finally succumbed to the tragedy of laminitis. Through his own research, Dr. Lawless had become familiar with the natural anti-inflammatory compound resveratrol. Resveratrol was receiving a great deal of recognition at that time due to it being the first compound identified to activate the “anti-aging gene” SIRT1. Pat realized that there was an opportunity to use resveratrol to help horses and dogs. In 2008, Dr. Lawless founded the company and developed the first equine product, Equithrive® Joint, to contain a purified form of resveratrol. Since then, Equithrive Joint has been evaluated in multiple university studies, where it has been proven to support soundness and mobility and to promote healthy levels of inflammation and free radicals in horses. The company then launched a higher dose resveratrol product (Metabarol™) that has been proven to support healthy metabolism in horses by maintaining appropriate insulin levels. Due to the success of Equithrive Joint and Metabarol, Dr. Lawless developed Petthrive to support joint health and metabolic health in dogs.